APCAP - activated protein C in acute pancreatitis: A double-blind randomized human pilot trial

Critical Care

Volumn 14, Issue 4, 2010, Pages

  Pettilä, Ville ^a,b   Kyhälä, Lea ^a   Kylänpää, Marja Leena ^a   Leppäniemi, Ari ^a   Tallgren, Minna ^a   Markkola, Antti ^a   Puolakkainen, Pauli ^a   Repo, Heikki ^c   Kemppainen, Esko ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; BILIRUBIN GLUCURONIDE; DROTRECOGIN; PLACEBO; BILIRUBIN; PROTEIN C; RECOMBINANT PROTEIN;

ACUTE PANCREATITIS; ADULT; AMYLASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SEQUENTIAL ORGAN FAILURE ASSESSMENT; ACUTE DISEASE; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; PANCREATITIS; PILOT STUDY; PROSPECTIVE STUDY; RADIOGRAPHY; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; BILIRUBIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PANCREATITIS; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTEIN C; RECOMBINANT PROTEINS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77954885617     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9203     Document Type: Article

References (37)

1. Frossard JL, Hadengue A, Pastor CM. New serum markers for the detection of severe acute pancreatitis in humans. Am J Resp Crit Care Med 2001, 164:162-170.
2. Halonen KI, Pettilä V, Leppäniemi AK, Kemppainen EA, Puolakkainen PA, Haapiainen RK. Multiple organ dysfunction associated with severe acute pancreatitis. Crit Care Med 2002, 30:1274-1279. 10.1097/00003246-200206000-00019, 12072681.
3. de Beaux AC, Palmer KR, Carter DC. Factors influencing morbidity and mortality in acute pancreatitis; an analysis of 279 cases. Gut 1995, 37:121-126. 10.1136/gut.37.1.121, 1382782, 7672660.
4. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26:1793-1800.
5. Ottesen LH, Bladbjerg EM, Osman M, Lausten SB, Jacobsen NO, Gram J, Jensen SL. Protein C activation during the initial phase of experimental acute pancreatitis in the rabbit. Dig Surg 1999, 16:486-495. 10.1159/000018774, 10805548.
6. Lindstrom O, Kylänpaa L, Mentula P, Puolakkainen P, Kemppainen E, Haapiainen R, Fernandez JA, Griffin JH, Repo H, Petäjä J. Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. Crit Care 2006, 10:R16. 10.1186/cc3966, 1550818, 16420659.
7. Alsfasser G, Warshaw AL, Thayer SP, Antoniu B, Laposata M, Lewandrowski KB, Fernandez-del Castillo C. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch Surg 2006, 141:670-676. 10.1001/archsurg.141.7.670, 16847238.
8. Chen P, Zhang Y, Qiao M, Yuan Y. Activated protein C, an anticoagulant polypeptide, ameliorates severe acute pancreatitis via regulation of mitogen-activated protein kinases. J Gastroenterol 2007, 42:887-896. 10.1007/s00535-007-2104-2, 18008033.
9. Yamanel L, Mas MR, Comert B, Isik AT, Aydin S, Mas N, Deveci S, Ozyurt M, Tasci I, Unal T. The effect of activated protein C on experimental acute necrotizing pancreatitis. Crit Care 2005, 9:R184-R190. 10.1186/cc3485, 1175873, 15987389.
10. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, . Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773, Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group.
11. Eichacker PQ, Natanson C. Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 2007, 33:396-399. 10.1007/s00134-007-0556-8, 17325833.
12. Mackenzie AF. Activated protein C: do more survive?. Intensive Care Med 2005, 31:1624-1626. 10.1007/s00134-005-2829-4, 16228174.
13. Woodward B, Cartwright M. Safety of drotrecogin alfa (activated) in severe sepsis: Data from adult clinical trials and observational studies. J Crit Care 2009, 24:595-602. 10.1016/j.jcrc.2008.11.011, 19327331.
14. Barie PS. "All in" for a huge pot: the PROWESS-SHOCK trial for refractory septic shock. Surg Infect (Larchmt) 2007, 8:491-494. 10.1089/sur.2007.9980, 17999581.
15. Kirschenbaum L, Astiz M. Acute pancreatitis: a possible role for activated protein C?. Crit Care 2005, 9:243-244. 10.1186/cc3515, 1175889, 15987410.
16. Jamdar S, Siriwardena AK. Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis. Crit Care 2005, 9:321-322. 10.1186/cc3777, 1269478, 16137370.
17. Bradley EL. A clinically based classification system for acute pancreatitis. Summary of the international symposium on acute pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993, 128:586-590.
18. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL, . Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332-1341. 10.1056/NEJMoa050935, 16192478, Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.
19. Nathens AB, Curtis JR, Beale RJ, Cook DJ, Moreno RP, Romand J-A, Skerrett SJ, Stapleton RD, Ware LB, Waldman CS. Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 2004, 32:2524-2536. 10.1097/01.CCM.0000148222.09869.92, 15599161.
20. Pettilä V, Pettilä M, Sarna S, Voutilainen P, Takkunen O. Comparison of multiple organ dysfunction scores in prediction of hospital mortality in the critically ill patients. Crit Care Med 2002, 28:1705-1711. 10.1097/00003246-200208000-00005, 12163780.
21. Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Crit Care 2008, 12:R161. 10.1186/cc7160, 2646326, 19091120.
22. Schoenfeld DA, Bernard GR, . ARDS Network Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002, 30:1772-1777. 10.1097/00003246-200208000-00016, 12163791, ARDS Network.
23. Mortele KJ, Wiesner W, Intriere L, Shankar S, Zou KH, Kalantari BN, Perez A, vanSonnenberg E, Ros PR, Banks PA, Silverman SG. A modified CT severity index for evaluating acute pancreatitis: improved correlation with patient outcome. AJR Am J Roentgenol 2004, 183:1261-1265.
24. Guyatt GH, Sackett DL, Cook DJ, . Evidence-Based Medicine Working Group User' s guides to the medical literature II. How to use an article about therapy or prevention B. What were the results and will they help me in caring for my patients?. JAMA 1994, 271:59-63. 10.1001/jama.271.1.59, 8258890, Evidence-Based Medicine Working Group.
25. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M, . Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH).
26. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G, Bernard GR, . Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003, 31:834-840. 10.1097/01.CCM.0000051515.56179.E1, 12626993, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group.
27. Machala W, Wachowicz N, Komorowska A, Gaszynski W. The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies. Med Sci Monit 2004, 10:CS31-CS36.
28. Ping C, Youngping Z, Minmin Q, Weiyan Y, Yaozong Y. Activated protein C improves severity of severe acute pancreatitis via up-regulating the expressions of endothelial cell protein C receptor and thrombomodulin. Dig Dis Sci 2009,
29. Akay S, Ozutemiz O, Yenisey C, Genc N, Yuce G, Batur Y. Use of activated protein C has no avail in the early phase of acute pancreatitis. HPB (Oxford) 2008, 10:459-463. 2597320, 19088933.
30. Nacira S, Ferhat M, Olivier D, Valerie C, Solene C, Chantal M, Sebastien G, Pierre A, Andriantsitohaina R, Veronique R, Michel S, Thomas L, Patrick L, Bruno L. Activated protein C improves LPS-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Crit Care Med 2008,
31. Iba T, Kidokoro A, Fukunaga M, Nagakari K, Shirahama A, Ida Y. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 2005, 33:368-372. 10.1097/01.CCM.0000153415.04995.88, 15699841.
32. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001, 29:S48-S51. discussion 51-52, 10.1097/00003246-200107001-00018, 11445734.
33. Neyrinck AP, Liu KD, Howard JP, Matthay MA. Protective mechanisms of activated protein C in severe inflammatory disorders. Br J Pharmacol 2009, 158:1034-1037. 10.1111/j.1476-5381.2009.00251.x, 19466992.
34. Radenkovic D, Bajec D, Karamarkovic A, Stefanovic B, Milic N, Ignjatovic S, Gregoric P, Milicevic M. Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis. Pancreas 2004, 29:152-156. 10.1097/00006676-200408000-00010, 15257107.
35. Turpin DL. CONSORT and QUOROM guidelines for reporting randomized clinical trials and systematic reviews. Am J Orthod Dentofacial Orthop 2005, 128:681-685. 10.1016/j.ajodo.2005.10.010, 16360902.
36. Takala J. Better conduct of clinical trials: the control group in critical care trials. Crit Care Med 2009, 37:S80-S90. 10.1097/CCM.0b013e3181922bf4, 19104230.
37. Juneja D, Gopal PB, Ravula M. Scoring systems in acute pancreatitis: Which one to use in intensive care units?. J Crit Care 2010, 25:. 10.1016/j.jcrc.2009.12.010, 20149591.